Skip to content

Inflammation in Vascular Disease

The Role of Inflammation in Vascular Disease (Inflammationens Roll i kärlsjukdom)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03732612
Acronym
REBEL
Enrollment
170
Registered
2018-11-06
Start date
2019-09-02
Completion date
2027-02-01
Last updated
2025-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Vascular Diseases

Brief summary

Increasing evidence suggests that systemic low-grade inflammation may be a driving force of cardiometabolic complications, such as vascular dysfunction, atherosclerosis and ischemic heart disease. Thus, we will investigate the role of inflammation in cardiovascular disease.

Detailed description

Vascular reconstruction surgeries usually require a small piece of the vessel wall to be excised. The excised vessel is generally discarded as medical waste: however, for patients participating in the study, the excised tissue will be placed in saline and collected for research use. Tissue collected from individuals undergoing vascular surgery associated with peripheral arterial diseases, aneurysm and/or other manifestations of atherosclerosis, vascular tissue will be cultured ex vivo in the presence or absence of therapeutic agents, to determine if these attenuate the inflammation associated with the atherosclerotic phenotype. Furthermore, the protocol will also be carried out using vascular tissue from control patients, which have undergone vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc).

Interventions

None listed

Sponsors

Göteborg University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patient is planned to undergo vascular surgery. * Signed informed consent has been obtained from the patient.

Exclusion criteria

* Patient has difficulty to understand information. * Patients under 18 years of age. * Patients participating in any drug-related study.

Design outcomes

Primary

MeasureTime frameDescription
Inflammatory status2019-2024The inflammatory status will be studied in patients with atherosclerotic disease.

Countries

Sweden

Contacts

Primary ContactEmma Borgeson, PhD
emma.borgeson@wlab.gu.se+46313420000
Backup ContactPer Skoog, MD, PhD
per.skoog@vgregion.se+46313420000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026